Cytokine therapy in rheumatoid arthritis [5]

Lancet

Volumn 348, Issue 9030, 1996, Pages 824-825

  Maini, R N ^a   Feldmann, M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLLAGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG TARGETING; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LETTER; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029845196     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)65243-9     Document Type: Letter

References (5)

1. M McCarthy Gene therapy for rheumatoid arthritis starts clinical trials Lancet 348 1996 323
2. PH Wooley JD Whalen DL Chapman The effects of interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice Arthritis Rheum 36 1993 1305 1314
3. MJ Elliott RN Maini M Feldmann Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a Arthritis Rheum 36 1993 1681 1690
4. MJ Elliott RN Maini M Feldmann Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor (X (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
5. ECC Rankin EHS Choy D Kassimos The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis Br J Rheum 34 1995 334 342